JP2024546989A - 治療用ペプチドの使用 - Google Patents

治療用ペプチドの使用 Download PDF

Info

Publication number
JP2024546989A
JP2024546989A JP2024536119A JP2024536119A JP2024546989A JP 2024546989 A JP2024546989 A JP 2024546989A JP 2024536119 A JP2024536119 A JP 2024536119A JP 2024536119 A JP2024536119 A JP 2024536119A JP 2024546989 A JP2024546989 A JP 2024546989A
Authority
JP
Japan
Prior art keywords
subject
peptide
disorder
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546989A5 (https=
Inventor
イゴール グラチェフ，
スイン ファン，
孝英 耕田
ハラルド マーク，
尚史 西田
耕作 大日向
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JP2024546989A publication Critical patent/JP2024546989A/ja
Publication of JP2024546989A5 publication Critical patent/JP2024546989A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024536119A 2021-12-15 2022-12-14 治療用ペプチドの使用 Pending JP2024546989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289915P 2021-12-15 2021-12-15
US63/289,915 2021-12-15
PCT/US2022/081558 WO2023114846A1 (en) 2021-12-15 2022-12-14 Uses of therapeutic peptides

Publications (2)

Publication Number Publication Date
JP2024546989A true JP2024546989A (ja) 2024-12-26
JP2024546989A5 JP2024546989A5 (https=) 2025-12-22

Family

ID=85157076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536119A Pending JP2024546989A (ja) 2021-12-15 2022-12-14 治療用ペプチドの使用

Country Status (5)

Country Link
US (1) US20250059233A1 (https=)
EP (1) EP4447987A1 (https=)
JP (1) JP2024546989A (https=)
CN (1) CN118785917A (https=)
WO (1) WO2023114846A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280202B2 (en) * 2015-03-02 2019-05-07 Kyoto University Peptide
WO2018047852A1 (en) 2016-09-07 2018-03-15 Kyoto University Peptides and peptide conjugates for treating mental disorders
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤
JP7787424B2 (ja) * 2021-02-04 2025-12-17 ユーハ味覚糖株式会社 デプレスタチン含有組成物の製造方法
JPWO2022186015A1 (https=) * 2021-03-02 2022-09-09
WO2022202985A1 (ja) * 2021-03-24 2022-09-29 森永乳業株式会社 ペプチド、及び該ペプチドを有効成分として含有する組成物

Also Published As

Publication number Publication date
US20250059233A1 (en) 2025-02-20
EP4447987A1 (en) 2024-10-23
WO2023114846A1 (en) 2023-06-22
CN118785917A (zh) 2024-10-15

Similar Documents

Publication Publication Date Title
Shi et al. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users
Leyton et al. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C] raclopride study in healthy men
Yang et al. Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine
Webster et al. Complement component C1q modulates the phagocytosis of Aβ by microglia
AU2020239245B2 (en) Synthetic neuromodulatory peptides
Kim et al. Therapeutic doses of buspirone block D3 receptors in the living primate brain
Gatley et al. PET imaging in clinical drug abuse research
Hou et al. Positron emission tomography molecular imaging of dopaminergic system in drug addiction
RU2500401C2 (ru) (4-метокси-7-морфолин-4-ил-бензотиазол-2-ил)амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты для лечения посттравматического стрессового расстройства
Hereta et al. Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats
Chou et al. Decreased brain serotonin transporter binding in the euthymic state of bipolar I but not bipolar II disorder: a SPECT study
ES2509270T3 (es) Terapia y prevención del alcoholismo
JP2021519349A (ja) 幻覚とそれに関連する病態の治療のための方法および組成物
Lee et al. Methamphetamine-sensitized mice are accompanied by memory impairment and reduction of N-methyl-d-aspartate receptor ligand binding in the prefrontal cortex and hippocampus
JP2022091961A (ja) 精神疾患を治療するためのペプチドおよびペプチドコンジュゲート
Zhang et al. Caffeine alleviate lipopolysaccharide-induced neuroinflammation and depression through regulating p-AKT and NF-κB
JP2024546989A (ja) 治療用ペプチドの使用
JP2020509057A (ja) 治療用ペプチド
He et al. Several considerations in using traditional Chinese patent medicine for cerebral infarction
Kim et al. The effect of olfactory training using Korean version odorants: a preliminary study
Hiramatsu et al. Involvement of κ-opioid and σ receptors in short-term memory in mice
Kumar Singh et al. Anti-aggressive, brain neurotransmitters and receptor binding study of Fumaria indica in rodents
Sumiyoshi Verbal memory
JP2025541312A (ja) Ａｖｐｒ１ａアゴニストの用途
Stephenson et al. The impact of antidepressants on sleep and anxiety: a comparative study of fluoxetine and dothiepin using the Leeds Sleep Evaluation Questionnaire

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212